Press Releases - Exact Sciences
WEBSep 16, 2024 · Exact Sciences Announces Second-Quarter 2024 Results. July 17, 2024. Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening. May 24, 2024. Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®.
Exact Sciences Presents Data Demonstrating Advancement in …
WEBSep 16, 2024 · Exact Sciences News(108) Partnerships(14) Recommended Content. July 17, 2024. Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening. May 24, 2024. Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ...
Exact Sciences’ colon cancer blood test shows initial promise - STAT
WEBBy Jonathan Wosen. Sept. 16, 2024. West Coast Biotech & Life Sciences Reporter. Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based ...
Exact Sciences stock spikes ahead of data read (NASDAQ:EXAS)
WEBSep 11, 2024 · Exact Sciences in license agreement with TwinStrand for nucleic acid sequencing Exact Sciences GAAP EPS of -$0.09 beats by $0.24, revenue of $699.26M beats by $9.16M Recommended For You
Exact Sciences says data support its colon cancer blood test
WEBSep 16, 2024 · Exact Sciences released data from a study of its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for colorectal cancer and 31.2% for advanced precancerous lesions. Specificity, a measure of how well a test identifies people who do not have cancer, was 90.1% for negative samples confirmed by colonoscopy.
News & Stories - Exact Sciences
WEBAug 20, 2024 · The Unseen Consequence of Covid-19 on Cancer Screenings. Don’t Let Age Fool You: Early Onset Colorectal Cancer is On the Rise. The Truth About Cancer: Debunking Five Myths about the Big C. Unlocking the Future of Cancer Diagnostics: Powerful Decision-Making to Enhance Patient Impact.
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
WEBJan 7, 2024 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue between $645.5 million and $647.5...
Exact Sciences Advances Early Cancer Detection and Precision …
WEBOct 20, 2023 · Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer...
Exact Sciences Launches Riskguard™ Hereditary Cancer Test in …
WEBFeb 28, 2024 · The Riskguard test provides an individualized patient report that includes gene specific and familial risks using a simple blood or saliva sample for 10 common cancers, including colorectal ...
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
WEBMADISON, Wis., Jan. 8, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report...